Related Experiment Video

Updated: Mar 25, 2026

A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

4.7K

Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly

Fabiola Olivieri1, Roberto Antonicelli, Maurizio Cardelli

  • 1Centre of Genetic and Molecular Biology, Research Department, Italian National Research Centre on Aging, Ancona, Italy. b.nolecolare@inrca.it

Mechanisms of Ageing and Development
|March 7, 2006
PubMed

Insights

Genetic factors influencing inflammation may impact cardiovascular disease (CVD) risk in older adults. Research into gene variants for inflammatory cytokines and immune receptors could personalize prevention and treatment strategies for myocardial infarction (MI).

Area of Science:

  • Gerontology and Cardiovascular Medicine
  • Immunology and Genetics

Background:

  • Cardiovascular diseases (CVD), including myocardial infarction (MI), are leading causes of mortality and disability in the elderly.
  • Aging is associated with increased inflammation, potentially contributing to CVD development, but underlying mechanisms require further elucidation.
  • Genetic and environmental factors interact in CVD pathogenesis, highlighting the need to identify genetic components of inflammatory risk factors.

Purpose of the Study:

  • To review the evidence for the role of genetic polymorphisms in inflammatory cytokines (IL-6, TNF-alpha, IL-10) and immune receptors (CD14, TLR-4) in modulating MI incidence and prognosis.
  • To focus on the implications of these genetic factors in the aging population.
  • To explore the potential for personalized prevention and therapy by understanding the genetic basis of inflammatory cardiovascular risk.

Main Methods:

  • Systematic review of existing literature on genetic polymorphisms of key inflammatory cytokines and immune receptors.
  • Analysis of studies investigating the association between these polymorphisms and the incidence or prognosis of myocardial infarction (MI).
  • Special emphasis on data pertaining to the aging population.

Main Results:

  • Conflicting data exists regarding the association between pro- and anti-inflammatory gene variants and CVD/MI.
  • Definitive evidence for the role of specific polymorphisms in MI pathogenesis is currently lacking.
  • Further research is needed to clarify the contribution of genetic variations in inflammatory pathways to cardiovascular disease in the elderly.

Conclusions:

  • Genetic polymorphisms of inflammatory cytokines and immune receptors may influence cardiovascular disease risk and outcomes, particularly in aging individuals.
  • Controlling inflammation through targeted therapies, informed by genetic predispositions, could offer a protective role against CVD.
  • More conclusive research is required to establish definitive links and leverage genetic insights for personalized cardiovascular medicine.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
943
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
560
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
438
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
736